The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
 
Katsunori Asai
Research Funding - Ono Pharmaceutical (Inst)
 
Yoshitaka Narita
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Novocure; Ono Pharmaceutical; Sumitomo Dainippon Pharma Oncology
Consulting or Advisory Role - Dainippon Sumitomo Pharma
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Ohara Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Stella pharma (Inst); Taiho Pharmaceutical (Inst)
 
Motoo Nagane
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin International; Nippon Kayaku; Novocure; Ohara Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Novocure; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma; CSL Behring (Inst); Daiichi Sankyo; Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); HOYA Techonosurgical (Inst); Kyowa Kirin International; Nippon Kayaku (Inst); Ono Pharmaceutical; Otsuka (Inst); Saney Seiko (Inst); Teijin Pharma (Inst)
Travel, Accommodations, Expenses - Denka Co., Ltd; Eisai; Nippon Kayaku; Ohara Pharmaceutical; Ono Pharmaceutical
 
Kazuhiko Mishima
Speakers' Bureau - Chugai Pharma; Eisai; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); Daiichi Sankyo Pharmaceutical (Inst); Eisai (Inst); Medical U and A, Inc (Inst); MSD (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Teijin Pharma (Inst)
 
Yasuhito Terui
Speakers' Bureau - Abbvie; Celgene; Chugai Pharma; Eisai; Janssen; Ono Pharmaceutical
 
Yoshiki Arakawa
Speakers' Bureau - Brainlab; Chugai Pharma; Daiichi Sankyo; Eisai; Merck; Nihon Medi-Physics; Nippon Kayaku; Novocure; Ono Pharmaceutical; UCB; Zeiss
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Japan Blood Products Organization (Inst); Nihon Medi-Physics (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Philips Healthcare (Inst); Siemens (Inst); Stryker (Inst); Sumitomo Dainippon Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Hajime Yonezawa
Research Funding - Ono Pharmaceutical (Inst)
 
Noriko Fukuhara
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; SymBio Pharmaceuticals
Research Funding - Abbvie (Inst); Chordia Therapeutics (Inst); Chugai Pharma (Inst); Genmab (Inst); Incyte (Inst); Incyte Japan (Inst); Kyowa Kirin International (Inst); Loxo/Lilly (Inst); Takeda (Inst)
 
Kazuhiko Sugiyama
Honoraria - Daiichi Sankyo Pharmaceutical; Eisai; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst)
 
Naoki Shinojima
Research Funding - Ono Pharmaceutical (Inst)
 
Arata Aoi
Employment - Ono Pharmaceutical
 
Ryo Nishikawa
Honoraria - Eisai; Nihonkayaku
Consulting or Advisory Role - Novocure; Springer
Speakers' Bureau - Ono Pharmaceutical; Varian Medical Systems
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst)